维力医疗
(603309)
| 流通市值：42.23亿 | | | 总市值：42.38亿 |
| 流通股本：2.92亿 | | | 总股本：2.93亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 745,161,624.74 | 348,152,134.38 | 1,509,335,256.03 | 1,060,429,057.46 |
| 营业收入 | 745,161,624.74 | 348,152,134.38 | 1,509,335,256.03 | 1,060,429,057.46 |
| 二、营业总成本 | 599,681,370.35 | 279,072,044.8 | 1,254,900,116.55 | 874,790,564.58 |
| 营业成本 | 409,560,013.62 | 192,256,355.32 | 837,189,388.83 | 585,377,707.53 |
| 税金及附加 | 10,123,699.17 | 4,320,619.64 | 16,313,055.07 | 11,244,847.93 |
| 销售费用 | 62,629,712.38 | 28,727,694.8 | 158,218,403.91 | 108,203,581.92 |
| 管理费用 | 62,914,737.54 | 30,232,203.45 | 129,920,814.45 | 97,387,037.62 |
| 研发费用 | 46,634,095.32 | 21,233,816.26 | 111,112,162.68 | 66,811,813.9 |
| 财务费用 | 7,819,112.32 | 2,301,355.33 | 2,146,291.61 | 5,765,575.68 |
| 其中:利息费用 | 8,786,344.13 | 2,346,564.4 | 12,315,532.14 | 7,688,612.54 |
| 其中:利息收入 | 3,264,530.51 | 1,142,746.16 | 5,631,835.85 | 4,820,310.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 326,183.14 | 628,851.62 | 619,061.73 | 171,547.83 |
| 加:投资收益 | 1,569,236.69 | 676,864.98 | 6,691,645.98 | 5,411,823.74 |
| 资产处置收益 | -2,304.82 | -2,304.82 | 428,433.91 | 67,434.79 |
| 资产减值损失(新) | -2,313,359.83 | -1,591,797.14 | -9,269,486.1 | 44,539.54 |
| 信用减值损失(新) | -263,362.4 | -57,850.18 | -18,466.35 | -28,490.69 |
| 其他收益 | 4,779,121.67 | 3,034,871.8 | 12,612,806.09 | 9,442,844.44 |
| 四、营业利润 | 149,575,768.84 | 71,768,725.84 | 265,499,134.74 | 200,748,192.53 |
| 加:营业外收入 | 292,090.78 | 58,221.63 | 347,683.57 | 526,276.07 |
| 减:营业外支出 | 320,410.22 | 124,480.18 | 2,803,286.49 | 2,094,074.82 |
| 五、利润总额 | 149,547,449.4 | 71,702,467.29 | 263,043,531.82 | 199,180,393.78 |
| 减:所得税费用 | 22,517,024.83 | 11,121,679.78 | 34,572,491.15 | 26,983,389.84 |
| 六、净利润 | 127,030,424.57 | 60,580,787.5 | 228,471,040.67 | 172,197,003.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 127,030,424.57 | 60,580,787.5 | 228,471,040.67 | 172,197,003.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 121,076,601.73 | 58,923,751.17 | 219,393,029.14 | 166,726,371.77 |
| 少数股东损益 | 5,953,822.84 | 1,657,036.33 | 9,078,011.53 | 5,470,632.17 |
| 扣除非经常损益后的净利润 | 117,620,532.54 | 56,645,532.5 | 210,024,675.08 | 160,016,558.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.2 | 0.75 | 0.57 |
| (二)稀释每股收益 | 0.41 | 0.2 | 0.75 | 0.57 |
| 八、其他综合收益 | 3,607,059.26 | 364,312.09 | -944,789.73 | - |
| 归属于母公司股东的其他综合收益 | 3,426,706.3 | 346,096.49 | -897,550.24 | - |
| 九、综合收益总额 | 130,637,483.83 | 60,945,099.59 | 227,526,250.94 | 172,197,003.94 |
| 归属于母公司股东的综合收益总额 | 124,503,308.03 | 59,269,847.66 | 218,495,478.9 | 166,726,371.77 |
| 归属于少数股东的综合收益总额 | 6,134,175.8 | 1,675,251.93 | 9,030,772.04 | 5,470,632.17 |
| 公告日期 | 2025-07-31 | 2025-04-25 | 2025-04-25 | 2024-10-19 |
| 审计意见(境内) | | | 标准无保留意见 | |